Andre Goy, MD
The FDA approval of ibrutinib (Imbruvica) in 2013 had a significant impact on the treatment landscape for patients with mantle cell lymphoma (MCL). However, the recent approval of acalabrutinib (Calquence) has similarly altered the field, as experts say it could be associated with slightly fewer adverse events (AEs) than ibrutinib, according to Andre Goy, MD.
The November 2017 approval for acalabrutinib was based on the findings from the phase II ACE-LY-004 trial, in which 124 patients with relapsed/refractory MCL received oral acalabrutinib at 100 mg twice daily. The investigator-assessed objective response rate was 81% (95% CI, 73%-87%). The complete response (CR) rate with acalabrutinib was 40% and the partial response (PR) rate was 41%.1
... to read the full story